The state’s Prescription Drug Price Transparency Program was created to illuminate pharmaceutical pricing practices, but pharmaceutical companies have shielded information they say infringes on trade secrets.
But they face drug industry opposition as they consider bills to make generic drugs more available, limit out-of-pocket insulin costs and set price limits on expensive drugs.